The pegfilgrastim biosimilars market provides more affordable alternatives to Neulasta, the leading therapy for cancer patients undergoing chemotherapy. Pegfilgrastim biosimilars work by stimulating the production of neutrophils, a type of white blood cell, to manage chemotherapy-induced febrile neutropenia. They offer comparable clinical benefits to Neulasta but at a much lower cost.... https://logcla.com/blogs/499016/Pegfilgrastim-Biosimilars-Market-to-Witness-High-Growth-Owing-to-Increasing